Drug-Eluting Balloon Registry in Routine Clinical Practice
IRIS DEB
Evaluation of Effectiveness and Safety of Drug-Eluting Balloon in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study
1 other identifier
observational
1,500
1 country
9
Brief Summary
The purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Longer than P75 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedFirst Submitted
Initial submission to the registry
January 15, 2014
CompletedFirst Posted
Study publicly available on registry
January 16, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
December 29, 2025
December 1, 2025
13 years
January 15, 2014
December 21, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composite Event
Death, Non-fatal myocardial infarction, Target vessel revascularization
1year
Secondary Outcomes (10)
All cause death
5year
Cardiac death
5year
Myocardial infarction
5year
Composite event
5year
Composite event
5year
- +5 more secondary outcomes
Study Arms (1)
Patients with coronary artery disease
Interventions
Eligibility Criteria
Patients treated with balloon angioplasty
You may qualify if:
- After pre dilatation residual stenosis 30% and less and also without vessel dissection interrupted blood flow
- Age 20 and more
- Treated with Balloon angioplasty
- Signed informed consent and agreed to follow protocol
You may not qualify if:
- Allergy to paclitaxel, antiplatelet
- History of side effect to heparin, aspirin, thienopyridines
- History of bleeding tendency, coagulation disorder, blood transfusion reaction
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CardioVascular Research Foundation, Koreacollaborator
- Seung-Jung Parklead
- B. Braun Korea Co., Ltd.collaborator
Study Sites (9)
Soon Chun Hyang University Hospital Bucheon
Bucheon-si, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
The Catholic University of Korea, Daejeon ST. Mary's Hospital
Daejeon, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Dong-A Medical Center
Pusan, South Korea
Asan Medical Center
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Ulsan University Hospital
Ulsan, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD,PhD
Study Record Dates
First Submitted
January 15, 2014
First Posted
January 16, 2014
Study Start
January 1, 2014
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
June 1, 2027
Last Updated
December 29, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share
This is not a publicly funded trial.